Imaging agents developed to better monitor growth of tumours

October 4, 2017
John Lewis (left) has led a team in creating two new imaging agents that can be used in PET scans and fluorescence imaging to visualize the formation of tumour-associated blood vessels and keep track of tumour growth. Credit: University of Alberta

UAlberta researchers have created two new imaging agents that could help physicians visualize the formation of tumour-associated blood vessels, keep track of tumour growth and possibly generate new therapies.

"Blood growth is critical to ," said John Lewis, the Alberta Cancer Foundation Frank and Carla Sojonky Chair in Prostate Cancer Research at the U of A and a member of the Cancer Research Institute of Northern Alberta (CRINA). "When a starts growing, cells start to divide out of control and they lack an organized blood vessel network to feed them. When that happens, there are help signals that tell the surrounding blood vessels to branch off and supply the tumour with new blood vessels for oxygen and nutrients."

The process is called angiogenesis. There are a number of approved cancer drugs to prevent the formation of new tumour-related blood vessels, but according to Lewis, many haven't yet lived up to their promise due to wide variability among . He believes the newly created imaging agents, which can be used in PET scans and fluorescence imaging, could provide physicians helpful insight when determining the best course of action for their patients.

"These drugs can be toxic and expensive, but potentially life-saving for certain patients. An imaging agent could be used before treatment to see how many new blood vessels are forming to determine whether an individual patient is a candidate for treatments that will inhibit new .' This would allow treatment to be personalized for those patients most likely to respond. Also, during the treatment, you could use the same imaging agent to monitor the response to the therapy."

In his research, Lewis, along with collaborators at Western University and Case Western Reserve University, worked with a protein, EGFL7, that is specific to actively growing vessels. Together they created new peptides that home into EGFL7 to test if they would be useful for imaging purposes.

"Once we had the peptide, we validated in two ways," said Lewis. "First we did some PET imaging of mice tumours and the peptide localized to those tumours and lit them up. We also created nanoparticles with the peptide and they were able to accumulate in the new and light them up as well."

The imaging agents now need to be tested in a treatment setting. Lewis plans to begin that work in animal models before moving on to clinical work in humans. His aim is to provide new tools which will help doctors make better and quicker treatment decisions for their patients.

"Ideally we would get a measure of response 24 hours after we first give the drug," said Lewis, "Currently we measure any changes in tumour size up to a month after , which is a long time to wait to find out if an expensive drug isn't working."

Explore further: New imaging technique spots prostate tumours starved of oxygen

More information: Choi-Fong Cho et al, Viral nanoparticles decorated with novel EGFL7 ligands enable intravital imaging of tumor neovasculature, Nanoscale (2017). DOI: 10.1039/C7NR02558K

Related Stories

New imaging technique spots prostate tumours starved of oxygen

August 24, 2017

A new imaging technique uncovers oxygen levels in prostate tumours and could lead to a non-invasive way to determine which tumours are more difficult to treat, according to a Cancer Research UK-funded study published in Theranostics.

A protein makes the difference

October 18, 2016

When tumours develop they absorb oxygen and nutrients from the surrounding tissue. Once the tumour reaches a certain size, this is no longer enough to allow it to continue growing. It needs new blood vessels to deliver oxygen ...

Recommended for you

Breakthrough in ultra-fast data processing at nanoscale

October 20, 2017

A research team from the National University of Singapore has recently invented a novel "converter" that can harness the speed and small size of plasmons for high frequency data processing and transmission in nanoelectronics.

Art advancing science at the nanoscale

October 18, 2017

Like many other scientists, Don Ingber, M.D., Ph.D., the Founding Director of the Wyss Institute, is concerned that non-scientists have become skeptical and even fearful of his field at a time when technology can offer solutions ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.